These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38968490)

  • 1. Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn's disease: A multi-center nationwide retrospective study (TARGET STUDY).
    Shehab M; Abdullah I; Alfadhli A; Alrashed F
    Medicine (Baltimore); 2024 Jul; 103(27):e38804. PubMed ID: 38968490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
    Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A
    Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study.
    Gómez Espín R; Nicolás De Prado I; Gil Candel M; González Carrión M; Rentero Redondo L; Iniesta Navalón C
    Rev Esp Enferm Dig; 2021 Feb; 113(2):110-115. PubMed ID: 33213170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
    Hanžel J; Zdovc J; Kurent T; Sever N; Javornik K; Tuta K; Koželj M; Smrekar N; Novak G; Štabuc B; Dreesen E; Thomas D; Vovk T; Grabnar I; Drobne D
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):111-118.e10. PubMed ID: 32109630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Hanžel J; Koželj M; Špes Hlastec A; Kurent T; Sever N; Zdovc J; Smrekar N; Novak G; Štabuc B; Grabnar I; Drobne D
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e831-e836. PubMed ID: 34402470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study.
    Rowan CR; Keegan D; Byrne K; Cullen G; Mulcahy HE; Sheridan J; Ryan EJ; de Vries A; D'Haens G; Doherty GA
    Aliment Pharmacol Ther; 2018 Aug; 48(3):333-339. PubMed ID: 29920697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
    Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
    Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
    Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
    Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Iborra M; Beltrán B; Fernández-Clotet A; Iglesias-Flores E; Navarro P; Rivero M; Gutiérrez A; Sierra-Ausin M; Mesonero F; Ferreiro-Iglesias R; Hinojosa J; Calvet X; Sicilia B; González-Muñoza C; Antolín B; González-Vivo M; Carbajo AY; García-López S; Martín-Cardona A; Surís G; Martin-Arranz MD; de Francisco R; Cañete F; Domènech E; Nos P;
    Aliment Pharmacol Ther; 2020 Sep; 52(6):1017-1030. PubMed ID: 32770851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
    Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
    Ollech JE; Normatov I; Peleg N; Wang J; Patel SA; Rai V; Yi Y; Singer J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT; Pekow J
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):104-110. PubMed ID: 32109634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
    Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
    Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
    [No Abstract]   [Full Text] [Related]  

  • 18. Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease.
    Vasudevan A; Tharayil V; Raffals LH; Bruining DH; Becker M; Murad MH; Loftus EV
    Inflamm Bowel Dis; 2024 Apr; 30(4):660-670. PubMed ID: 37071852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
    Iborra M; Beltrán B; Fernández-Clotet A; Gutiérrez A; Antolín B; Huguet JM; De Francisco R; Merino O; Carpio D; García-López S; Mesonero F; Navarro P; Ferreiro-Iglesias R; Carbajo AY; Rivero M; Gisbert JP; Piñero-Pérez MC; Monfort D; Bujanda L; García-Sepulcre MF; Martín-Cardona A; Cañete F; Taxonera C; Domènech E; Nos P;
    Aliment Pharmacol Ther; 2019 Aug; 50(3):278-288. PubMed ID: 31222872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
    Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
    Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.